Harmony Biosciences Holdings Inc 2026年季度报告

For the Quarterly Period Ended March 31, 2026OR Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant wasrequired to file such reports), and (2)has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for suchshorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “acceleratedfiler,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act: Largeacceleratedfiler☒Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section13(a)of theExchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ As of May 5, 2026, there were 57,892,676 shares of the registrant’s common stock, par value $0.00001 valueper share, outstanding. TABLE OF CONTENTS PagePartI. Financial Information3Item1. Financial Statements3Condensed Consolidated Balance Sheets (Unaudited)3Condensed Consolidated Statements of Operations and ComprehensiveIncome (Unaudited)4Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)5Condensed Consolidated Statements of Cash Flows (Unaudited)6Notesto Condensed Consolidated Financial Statements (Unaudited)7Item2. Management’s Discussion and Analysis of Financial Condition and Resultsof Operations27Item3. Quantitative and Qualitative Disclosures About Market Risk42Item4. Controls and Procedures43PartII. Other Information44Item1. Legal Proceedings44Item1A. Risk Factors44Item2. Unregistered Sales of Equity Securities and Use of Proceeds44Item3. Defaults upon Senior Securities44Item4. Mine Safety Disclosures44Item5. Other Information44Item6. Exhibits45Signatures46 PARTI. FINANCIAL INFORMATION HARMONY BIOSCIENCES HOLDINGS,INC. AND SUBSIDIARIESUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except share and per share data) The accompanying notes are an integral part of the unaudited condensed consolidatedfinancial statements HARMONY BIOSCIENCES HOLDINGS,INC. AND SUBSIDIARIESUNAUDITED CONDENSED CONSOLIDATEDSTATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME(In thousands, except share and per share data) Three Months Ended March31,20262025Net product revenue$215,387$184,733Cost of product sold44,51231,994Gross profit170,875152,739Operating expenses:Research and development69,38334,540Sales and marketing31,69430,711General and administrative32,50731,243Total operating expenses133,58496,494Operating income37,29156,245Other expense, net(127)(276)Interest expense(3,234)(3,836)Interest income5,7575,044Income before income taxes39,68757,177Income tax expense(7,199)(11,617)Net income$32,488$45,560Unrealized (loss) income on investments(759)179Comprehensive income$31,729$45,739EARNINGS PER SHARE:Basic$0.56$0.79Diluted$0.55$0.78Weighted average number of shares of common stock -basic57,819,06057,309,938Weighted average number of shares of common stock -diluted58,776,29758,524,566 HARMONY BIOSCIENCES HOLDINGS,INC. AND SUBSIDIARIESUNAUDITED CONDENSED CONSOLIDATEDSTATEMENTS OF STOCKHOLDERS’ EQUITY(In thousands, except share and per share data) Theaccompanying notes are an integral part of the unaudited condensed consolidatedfinancial statements HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIESUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands, except share and per share data) Three Months EndedMarch31,20262025CASH FLOWS FROM OPERATING ACTIVITIESNet income$32,488$45,560Adjustments to reconcile net income to net cash used in operating activities:Depreciation77Intangible amortization5,9615,961Acquired in-process research & development (IPR&D) expense32,000—Stock-based compensation10,62012,499Stock appreciation rights market adjustment(312)(49)Debt issuance costs amortization151166Deferred taxes(3,863)(4,311)Amortization of premiums and accretion of discounts on investment securities(220)(451)Other non-cash expenses560467Change in operating assets and liabilities:Trade receivables(11,435)(22,936)Inventory76814Prepaid expenses and other assets(2,996)(1,999)Trade payables10,9073,715Other liabilities(46,184)(5,456)Net cash provided by operating activities27,76033,987CASH FLOWS FROM INVESTING ACTIVITIES:Purchase of investment